Emgality

Emgality (galcanezumab) is a prescription medication used to prevent migraine headaches. This subcutaneous injection is designed to reduce the frequency of migraine episodes in eligible patients.

Emgality is primarily used for the preventive treatment of migraines. It is not intended for the acute treatment of migraines once they have started. The medication works by targeting a protein involved in the pathogenesis of migraines, helping to reduce the number of migraine days experienced by patients. Emgality is often considered when other preventive treatments have not been effective.

Common effects of Emgality may include injection site reactions such as redness, pain, or swelling. Some patients may also experience constipation, upper respiratory infection, or muscle pain. These effects are generally mild to moderate and may resolve on their own. It is important to consult a healthcare provider if any effects are severe or persistent.

Emgality should be used with caution in patients with a history of severe hypersensitivity to galcanezumab or any of its components. It is important to inform your healthcare provider about all medical conditions and medications you are currently taking. Emgality is administered via subcutaneous injection, and proper technique should be followed to minimize the risk of infection or other complications.

Emgality may interact with other medications, including those that affect the immune system or blood pressure. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy or safety of Emgality, so it is advisable to consult a healthcare provider before making any changes to your regimen.